ABIOMED Stock News

Abiomed, Inc. (ABMD) CEO Mike Minogue on Q2 2021 Results - Earnings Call Transcript

DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the first two patients have been treated with the Impella ECP expandable percutaneous heart pump. Impella ECP is the smallest heart pu

（ビジネスワイヤ） -- 急性心筋梗塞に伴う心原性ショック（AMICS）患者を対象とした2つの研究で、PCI前にImpellaを留置した場合、PCI後にImpellaを留置�

Capital Investment Advisory Services LLC decreased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 5.5% during the third quarter, according to the company in its most recent filing with the SEC.

（ビジネスワイヤ） -- Restore EF試験により、 Impella補助下の高リスクPCIでより完全な血行再建を試みたケースを含め、最新のベストプラクティスの使�

IBM Retirement Fund boosted its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 39.0% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Comm

Wie zwei Studien an Patienten mit akutem Myokardinfarkt und kardiogenem Schock (AMICS) zeigen, ist die Überlebensrate beim Einsatz von Impella vor ein

Abiomed (NASDAQ: ABMD) meldet neue Daten aus der Studie PROTECT III. Diese zeigen geringere MACCE-Raten (MACCE = Major Adverse Cerebrovascular and Car

Abiomed (NASDAQ: ABMD) announces new PROTECT III study data that demonstrates reduced rates of MACCE (composite of death, stroke, myocardial infarctio

Crossmark Global Holdings Inc. decreased its position in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 4.3% during the third quarter, according to its most recent Form 13F filing with the Securities & Exch

The Restore EF Study demonstrates the use of contemporary best practices, including attempting a more complete revascularization with Impella-supporte

Abiomed is definitely not cheap, but there is significant upside left in this stock.